Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer

NCT00777101 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT00777101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00777101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 4, 2009
Completion date
June 3, 2018
Enrollment
233 (actual)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer